Skip to main content

Venture Day with Medicxi, Venrock & Osage University Partners

When:

June 19, 2019 12:15 pmJune 19, 2019 2:00 pm (PDT)

Where:

The Alexandria at Torrey Pines
10996 Torreyana Road
San Diego, CA 92121

Registration Closed


Venture Day with Medicxi and Osage University Partners – San Diego


Biocom is pleased to announce our next exclusive Biocom Venture Day with three prestigious, active venture capitalists for a series of one-on-one meetings with selected members, scheduled to take place on June 19th. As part of the day long event, Jon Edwards, Partner, Medicxi, Matthew Cohen, Partner, Osage University Partners and Racquel Bracken, Vice President, Venrock will participate in a panel discussion moderated by Matthew Kim, Managing Director, Jefferies LLC.

Medicxi is a European venture capital firm with the mission to create and invest in companies along the full drug development continuum. Medicxi was established by the former Index Ventures life sciences team, which has been active for over 20 years, and invests in both early and late-stage assets with a product vision that can fulfill a clear unmet need. GSK, Johnson & Johnson, Novartis and Verily, an Alphabet company, have invested in Medicxi funds.

Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock partners with entrepreneurs to build some of the world’s most disruptive, successful companies. With a primary focus on technology and healthcare, portfolio companies have included Apple Computer, AveXis, Centocor, Check Point Software, Dollar Shave Club, DoubleClick, Gilead Sciences, Idec Pharma, Illumina, Intel, Juno Therapeutics, Millennium Pharma and Nest.

OUP (Osage University Partners) is a venture capital firm focused on investing in startups that are commercializing pioneering university technologies. OUP partners with top research universities to invest in their most innovative startups, and OUP shares its investment profit with its partner institutions. The firm invests in life science, software, and hardware companies at all stages of company development. OUP has partnered with 100 universities, including 39 of the top 50 U.S. institutions by research expenditures, and has invested in over 90 of their spinouts. OUP is part of a family of investment funds within Osage Partners, which is based in Philadelphia, PA and manages in excess of $800 million.

Biocom will host a complimentary panel discussion moderated by Jeffries in San Diego on June 19th. Space is limited and registration is required. Before and following the panel discussion,each investment entitiy will meet with pre-selected companies working in their areas of interest that align with their investment strategy.

Venture Day Agenda
  • 10:30am – 12:30pm: One-on-One Meetings*
  • 12:15pm – 1:00pm: Registration, Lunch & Networking
  • 1:00pm – 2:00pm: Panel Discussion
    • Medicxi & Osage University Partners Overview
    • Jon Edwards, Medicxi, Matthew Cohen, OUP, and Racquel Braken, Venrock
    • Moderated by Matthew Kim, Managing Director, Jefferies
  • 2:00pm – 5:30pm: One-on-One Meetings*
*Please note that registering for the event does not guarantee a meeting with the VCs; you must submit an application. Applications are now closed.



In Partnership with:
User-added image User-added image User-added image

Price of Admission

Biocom Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2019-06-12

0

Refund before

Refund Before

Non-Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2019-06-12

0

Refund before

Refund Before

Non-Member

Today’s Price: 0

Important Dates

Amount

Registration before

Registration before

Registration before

Registration cost

0

Refund before 2019-06-12

0

Refund before

Refund Before

  • Areas of Interest
     Osage Univsersity Partners (OUP)

    Early stage therapeutics –
    • Modality and indication agonistic. We focus on novel biology identifying new targets and pathways to drug for therapeutic effect; and novel modality platforms. We gravitate to pre-clinical opportunities where there are compelling mechanistic, cell, human genetic, and/or animal model proof of concept data, and invest through pre-clinical and into clinical proof of concept. We also will consider later-stage opportunities for companies already in the clinic or with existing clinical data
    • We will invest up to $15M per company over the life of the investment and are willing to lead for select opportunities
    Research Tools and Devices
    • OUP has limited investment in research tools and devices. Within research tools, we are most interested in next-generation genomic and proteomic platforms. Within devices, we are interested in opportunities to change standard of care through improvement of patient outcomes and prefer to see early human proof of concept prior to investment.
    Medicxi

    Life Science Therapeutics –
    • We are equally comfortable investing at a very early-stage of drug development, when candidate drugs have just been discovered and are entering preclinical stage, as well as at later stages of clinical development.
      • We back scientists that we believe can become future industry leaders: smart and insightful, driven by clear product vision, comfortable in unchartered territory, sharp, independent decision makers, ready to change direction when the data speaks. In short, we aspire to back true entrepreneurs with global ambitions.
    • At the early stages, we help start companies under our Asset Centric approach and support their development from scientific insight to early clinical studies and Proof-of-Concept (PoC). We start and grow our early-stage companies out of labs, academia or Pharma, and manage them as virtual companies following our Asset Centric approach.
      • The ones that successfully grow from their pre-clinical stage to early clinical and PoC are then ready for strategic transactions with Pharma or further development into later stages.
    • The recent addition of our Medicxi Growth fund extends our platform capabilities to support entrepreneurial teams when it makes strategic sense to build a long lasting biotech company well beyond the early stages of its development. Our growth fund is focused on supporting companies that have successfully reached clinical PoC and that we feel should develop their compounds independently through Ph2/3, FDA approval and market entry.
     
  • Speakers
    User-added image
    Matthew Cohen, Partner, Osage University Partners (OUP)
    Matt is a Partner at Osage University Partners (OUP) where he has focused on Life Science investments since 2013. He has participated in sourcing and diligence for many of OUP’s investments and is a board observer at Arrakis Therapeutics, Capella Bioscience, Faraday Pharma, and PMV Pharma. Prior to joining OUP, Matt was a strategy consultant with L.E.K. Consulting serving clients in biopharma, diagnostics, research tools, healthcare, and private equity. Matt holds a Ph.D. in Cell and Molecular Biology from The University of Pennsylvania, and a B.S. in Microbiology from The Pennsylvania State University.

    User-added image
    Jon Edwards, Partner, Medicxi
    Jon is a Partner at Medicxi and has been with the firm since its inception in 2016. Prior to joining Medicxi, Jon was an Associate at Index Ventures for two years, having joined in 2014. He led Medicxi’s investment in Synthorx and currently serves on the boards of a number of portfolio companies, including Palladio Biosciences, Xenikos, Z-Factor, UltraHuman and Sydnexis. Jon was also previously a director of Impact Biomedicines (acquired by Celgene). Prior to Index, Jon was a life sciences strategy consultant at ClearView Healthcare Partners. Jon received a Ph.D. in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill and conducted postdoctoral research at MIT.

    User-added image
    Racqel Bracken, Vice President, Venrock

    Racquel Bracken joined Venrock in 2016 and focuses on pharmaceutical and biotech investments. She currently serves on the Board of Cyteir Therapeutics, is a Board Observer at Inscripta, and is co-founder and CEO of Comet Medicine. Prior to Venrock, Racquel was an early employee of Clovis Oncology, a biopharmaceutical company focused on acquiring, developing and commercializing targeted small molecule therapies in combination with companion diagnostics. She held a variety of business development and commercial roles and was responsible for the acquisition of four pipeline products, and led the commercial launch efforts for the PARP inhibitor program in ovarian cancer. Earlier in her career, Racquel was on the investment team at Domain Associates where she focused on early-stage healthcare investing. During her tenure there, Racquel also led business development at Calixa Therapeutics (acquired by Cubist Pharmaceutical). Prior to joining Domain Associates, she was a consultant with Easton Associates (now Navigant Consulting), a management consultancy dedicated to the medical industry. Racquel is an avid backcountry skier, mountaineer, and mountain biker as well as a supporter of high school debate programs. She holds a bachelor’s degree in molecular and cellular biology from Harvard University and is also a member of the Kauffman Fellows.

     

Registration Closed